Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
67 hedge funds and large institutions have $416M invested in Adaptimmune Therapeutics in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 6 closing their positions.
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
93% more capital invested
Capital invested by funds: $216M → $416M (+$200M)
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
20% more funds holding
Funds holding: 56 → 67 (+11)
1.71% more ownership
Funds ownership: 30.82% → 32.53% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$20.9M |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$4.38M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.57M |
| 4 |
GAMA
Graticule Asia Macro Advisors
New York
|
+$2.47M |
| 5 |
Millennium Management
New York
|
+$2.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$5.34M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$3.32M |
| 3 |
QF
QVT Financial
New York
|
-$3.13M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.45M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.84M |
ADAP Hedge Fund Activity: Q3 2017 in Review
67 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2017, worth a combined $416M — up 93% from $216M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ADAP positions and 6 closed out — a net gain of 12 holders — while 21 added to existing stakes and 14 trimmed.
The largest buyer was Matrix Capital Management Company, adding an estimated $20.9M. The largest seller was Hillhouse Investment Management, exiting entirely with an estimated $5.34M sold.
- 67 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2017, up from 56 in Q2 2017.
- Funds reported $416M of Adaptimmune Therapeutics stock for Q3 2017, up 93% quarter-over-quarter.
- 18 funds opened new Adaptimmune Therapeutics positions in Q3 2017 and 6 closed out, a net change of +12 holders.
- The largest Adaptimmune Therapeutics buyer in Q3 2017 was Matrix Capital Management Company, an estimated $20.9M added.
- The largest Adaptimmune Therapeutics seller in Q3 2017 was Hillhouse Investment Management, an estimated $5.34M sold.
Based on aggregated 13F filings for Q3 2017.